Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UPP1 | Q16831 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.49 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HBB | P68871 | 1/20 | 0.44 |
| ▸ | TK1 | P04183 | 2/20 | 0.40 |
| ▸ | PYGM | P11217 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10458521 | 0.81 | UPP1 (0.57) | UPP1BLMHSD17B10USP2PNP | |
| SCHEMBL4088248 | 0.81 | UPP1 (0.57) | UPP1 | |
| SCHEMBL3786418 | 0.81 | UPP1 (0.57) | UPP1BLMHSD17B10CYP1A2GRIA1 | |
| SCHEMBL10457858 | 0.81 | UPP1 (0.57) | UPP1BLMHSD17B10CYP1A2GRIA1 | |
| SCHEMBL1838508 | 0.77 | UPP1 (0.53) | UPP1BLMHSD17B10USP2PNP | |
| SCHEMBL9016400 | 0.77 | UPP1 (0.53) | UPP1BLMHSD17B10USP2PNP | |
| Iodacyclur SCHEMBL3412826 | 0.76 | BLM (0.51) | UPP1BLMHSD17B10CYP1A2GRIA1 | |
| SCHEMBL10456669 | 0.76 | GRIA1 (0.53) | UPP1BLMHSD17B10GRIA1GRIA2 | |
| SCHEMBL3412829 | 0.76 | KMT2A (0.48) | UPP1BLMHSD17B10CYP1A2GRIA1 | |
| SCHEMBL10457857 | 0.73 | DGKA (0.48) | BLMHSD17B10CYP1A2GRIA1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227594-B2 | Antiviral nucleosides | Kumar, Rakesh (CA) | 2012-07-24 | — | — | US | disclosed |
| US-8227594-B2 | Antiviral nucleosides | Kumar, Rakesh (CA) | 2012-07-24 | — | — | US | disclosed |
| US-8227594-B2 | Antiviral nucleosides | Kumar, Rakesh (CA) | 2012-07-24 | — | — | US | disclosed |
| EP-2322534-A1 | Antiviral nucleosides | Kumar, Rakesh (CA) | 2011-05-18 | — | — | EP | disclosed |
| US-20100130440-A1 | ANTIVIRAL NUCLEOSIDES | KUMAR, RAKESH (CA) | 2010-05-27 | — | — | US | disclosed |
| US-20100130440-A1 | ANTIVIRAL NUCLEOSIDES | KUMAR, RAKESH (CA) | 2010-05-27 | — | — | US | disclosed |
| US-20100130440-A1 | ANTIVIRAL NUCLEOSIDES | KUMAR, RAKESH (CA) | 2010-05-27 | — | — | US | disclosed |
| US-7589077-B2 | such as 5-iodo-O6-5'-cyclo-5,6-dihydro-3'-azido-3'-deoxythymidine for prophylaxis or diagnosis of viral diseases caused by hepatitis virus, herpes viruses such as Epstein-Barr virus | Kumar, Rakesh (CA) | 2009-09-15 | — | — | US | disclosed |
| US-7589077-B2 | such as 5-iodo-O6-5'-cyclo-5,6-dihydro-3'-azido-3'-deoxythymidine for prophylaxis or diagnosis of viral diseases caused by hepatitis virus, herpes viruses such as Epstein-Barr virus | Kumar, Rakesh (CA) | 2009-09-15 | — | — | US | disclosed |
| US-7589077-B2 | such as 5-iodo-O6-5'-cyclo-5,6-dihydro-3'-azido-3'-deoxythymidine for prophylaxis or diagnosis of viral diseases caused by hepatitis virus, herpes viruses such as Epstein-Barr virus | Kumar, Rakesh (CA) | 2009-09-15 | — | — | US | disclosed |
| US-20040242533-A1 | Antiviral nucleosides | KUMAR, RAKESH (CA) | 2004-12-02 | — | — | US | disclosed |
| EP-1387850-A2 | ANTIVIRAL NUCLEOSIDES | Kumar, Rakesh (CA) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002094844-A2 | ANTIVIRAL NUCLEOSIDES | KUMAR RAKESH (CA) | 2002-11-28 | — | — | WO | disclosed |
| US-4916121-A | PHOSPHORYLASE INHIBITOR | TEIJIN LIMITED (JP) | 1990-04-10 | — | — | US | disclosed |
| EP-0202056-B1 | ANTITUMOR AGENT | TEIJIN LIMITED (JP) | 1989-08-30 | — | — | EP | disclosed |
| EP-0202056-A1 | Antitumor agent | TEIJIN LIMITED (JP) | 1986-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242533-A1 | Antiviral nucleosides | ENTPD5, DUT, ADA | UPP1 92/4885BLM 1135/4885HSD17B10 1640/4885 |
| US-20100130440-A1 | ANTIVIRAL NUCLEOSIDES | PNP, ENTPD5, ADA | UPP1 64/4885BLM 856/4885HSD17B10 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.